Video

Dr. McKay on the Design of the PDIGREE Trial in Advanced RCC

Rana R. McKay, MD, discusses the design of the phase 3 PDIGREE study in advanced renal cell carcinoma.

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the design of the phase 3 PDIGREE study in advanced renal cell carcinoma (RCC).

The PDIGREE trial is evaluating standard nivolumab (Opdivo) plus ipilimumab (Yervoy), says McKay. Patients who achieve a complete response (CR) will continue on nivolumab maintenance therapy while patients who have progressive disease will discontinue immunotherapy and receive cabozantinib (Cabometyx).

Patients who do not have a CR or progressive disease will be randomized to receive the combination of nivolumab and cabozantinib or nivolumab alone, adds McKay.

The study could provide insight on whether sequencing checkpoint inhibitors is optimal for patients with RCC, says McKay. Moreover, in the context of the CheckMate-9ER study investigating frontline nivolumab/cabozantinib, findings from the PDIGREE trial could have profound clinical implications.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity